Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 377 |
| Active Pipeline (Recruiting Now) | 143 (81) |
| Completed vs Stopped Early | 161 / 73 (19.4%) |
| Median Closed Actual Enrollment | 241 participants |
| Physical Hospital Site Disclosure | 99.9% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 418 (34 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| National Taiwan University Hospital | Taipei | 66 |
| Hospital Universitario 12 de Octubre | Madrid | 53 |
| Severance Hospital, Yonsei University Health System | Seoul, Other | 48 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05623020 | A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Le | Phase III | RECRUITING |
| NCT05611801 | A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B | Phase III | RECRUITING |
| NCT06698796 | A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies | Phase III | RECRUITING |
| NCT06807281 | A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema | Phase III | RECRUITING |
| NCT05145127 | Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors | Phase III | RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the Pfizer Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.